Abstract | AIMS AND BACKGROUND: PATIENTS AND METHODS: Sixteen VS in 14 patients with NF2 were treated with FSRT (n = 14) and SRS (n = 2). Patients with tumor progression and/or progression of clinical symptoms were selected for treatment. For patients treated with FSRT a median total dose of 57.6 Gy was prescribed with a median fractionation of 5 × 1.8 Gy per week. For patients who underwent SRS a median single dose of 17 Gy was prescribed to the 80% isodose. RESULTS: FSRT and SRS were well tolerated. Local control rate was 94% for a median follow-up time of 131 months; 2- and 5-year progression-free survival were 100%. The probability of maintaining the pretreatment hearing level was 44%. Useful hearing preservation was 33%. Cranial nerve toxicity was moderate. Trigeminal nerve function worsened in 2 patients (12%) and facial nerve function in 3 patients (19%). One patient developed a new tinnitus. CONCLUSION: FSRT and SRS are both safe and effective noninvasive and minimally invasive treatment options for patients with VS in the setting of NF2. The long-term local control rates are excellent. Functional hearing preservation is worse in patients with VS and NF2 than in patients with sporadic VS.
|
Authors | Johanna Wagner, Thomas Welzel, Daniel Habermehl, Jürgen Debus, Stephanie E Combs |
Journal | Tumori
(Tumori)
2014 Mar-Apr
Vol. 100
Issue 2
Pg. 189-94
ISSN: 2038-2529 [Electronic] United States |
PMID | 24852864
(Publication Type: Journal Article)
|
Topics |
- Adult
- Disease-Free Survival
- Dose Fractionation, Radiation
- Facial Nerve
(physiopathology, radiation effects)
- Female
- Follow-Up Studies
- Hearing
- Hearing Loss
(etiology)
- Humans
- Male
- Middle Aged
- Neurofibromatosis 2
(complications, physiopathology, surgery)
- Neuroma, Acoustic
(complications, physiopathology, surgery)
- Radiosurgery
(methods)
- Tinnitus
(etiology)
- Treatment Outcome
- Trigeminal Nerve
(physiopathology, radiation effects)
- Young Adult
|